Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hikma Pharmaceuticals Plc ADR (OP:HKMPY)

46.95 -1.05 (-2.20%)
Streaming Delayed Price Updated: 9:52 AM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hikma Pharmaceuticals Plc ADR

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada 
From Emergent BioSolutions
Via GlobeNewswire
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
From Junshi Biosciences
Via GlobeNewswire
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
From Bio-Thera Solutions, Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.